Repros Therapeutics (RPRX) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Repros Therapeutics Inc.® Reports Third Quarter 2016 Financial Results
November 8, 2016 4:00 PM ESTTHE WOODLANDS, Texas, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq: RPRX) today announced financial results for the third quarter ended September 30, 2016.
Financial Results
Net loss for the three month period ended September 30, 2016, was ($4.2) million or ($0.17) per share as compared to a net loss of ($6.6) million or ($0.27) per share for the same period in 2015. The net loss for the nine month period ended September 30, 2016, was ($13.3) million or ($0.55) per share as compared to a net loss of ($22.9) million or ($0.94) per... More
